Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6248551 | 0.84 | TSHR (0.69) | LMNAKEAP1HSPA5TSHRSLC7A5 | |
| SCHEMBL14541452 | 0.84 | LMNA (0.67) | LMNAKMT2ATSHRMAOBSMN1; SMN2 | |
| Acetic Acid SCHEMBL9081320 | 0.83 | KEAP1 (0.62) | LMNAKMT2AKEAP1HSPA5SLC7A5 | |
| SCHEMBL30616875 | 0.82 | KEAP1 (0.86) | KMT2AKEAP1HSPA5TSHRPKM | |
| SCHEMBL9776607 | 0.82 | KEAP1 (0.86) | KMT2AKEAP1HSPA5TSHRPKM | |
| SCHEMBL11150843 | 0.82 | LMNA (0.65) | LMNAKMT2ATSHRMAOBSMN1; SMN2 | |
| SCHEMBL4001426 | 0.82 | PLA2G10 (0.65) | LMNAKEAP1HSPA5TSHRSLC7A5 | |
| SCHEMBL2579068 | 0.81 | KEAP1 (0.56) | LMNAKEAP1HSPA5TSHRMAPT | |
| SCHEMBL12812400 | 0.81 | LMNA (0.62) | LMNAKMT2ATSHRMAOBPKM | |
| SCHEMBL6246739 | 0.79 | HSP90AA1 (0.56) | LMNAKMT2AKEAP1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414072-B2 | Aryl 5-thio-β-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-19 | — | — | US | disclosed |
| CN-100341885-C | Process for selective production of aryl 5-thio-beta-d-aldohexopyranosides | TAISHO PHARMACEUTICAL CO LTD (JP) | 2007-10-10 | — | — | CN | disclosed |
| US-7250522-B2 | Method for selective preparation of aryl 5-thio-β-D-aldohexopyranosides | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-31 | — | — | US | disclosed |
| CN-1312165-C | Aryl 5-thio-beta-D-glucopyranoside derivative and therapeutic agent for diabetes containing the same | TAISHO PHARMACEUTICAL CO LTD (JP) | 2007-04-25 | — | — | CN | disclosed |
| US-20050256317-A1 | Process for selective production of aryl 5-thio-beta-d- aldohexopyranosides | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| CN-1675233-A | Process for selective production of aryl 5-thio-beta-d-aldohexopyranosides | TAISHO PHARMACEUTICAL CO LTD (JP) | 2005-09-28 | — | — | CN | disclosed |
| US-20050209309-A1 | Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-22 | — | — | US | disclosed |
| CN-1639180-A | Aryl 5-thio-beta-D-glucopyranoside derivatives and remedies for diabetes containing the same | TAISHO PHARMACEUTICAL CO LTD (JP) | 2005-07-13 | — | — | CN | disclosed |
| EP-1541578-A1 | PROCESS FOR SELECTIVE PRODUCTION OF ARYL 5-THIO-BETA-D-ALDOHEXOPYRANOSIDES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1528066-A1 | ARYL 5-THIO-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256317-A1 | Process for selective production of aryl 5-thio-beta-d- aldohexopyranosides | ALDOA, DERA, AKR1D1 | LMNA 4746/4885KMT2A 3446/4885KEAP1 1983/4885 |
| US-20050209309-A1 | Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same | SLC5A2, SLC5A1, UGGT1 | LMNA 4370/4885KMT2A 1778/4885KEAP1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.